# PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
Canonical URL: https://biopharmsignal.com/news/PTCT/ptc-therapeutics-provides-corporate-update-and-reports-first-quarter-2026-financial-results
Ticker: PTCT
Company: PTC Therapeutics, Inc.
Source: PTC Therapeutics, Inc.
Published: 2026-05-07 20:01 EST
Original Source URL: https://ir.ptcbio.com
## Summary

– First quarter 2026 total revenue of $273 million, including $226 million of product revenue, supporting full-year 2026 guidance raise –    – Global Sephience™ (sepiapterin)   launch momentum continues with first quarter 2026 revenue of $125 million, representing 36% quarter-over-quarter growth –

## Article Body
– First quarter 2026 total revenue of $273 million, including $226 million of product revenue, supporting full-year 2026 guidance raise –    – Global Sephience™ (sepiapterin)   launch momentum continues with first quarter 2026 revenue of $125 million, representing 36% quarter-over-quarter growth –
## Recent Company News
- 2026-05-07 20:01 EST — [PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/PTCT/ptc-therapeutics-provides-corporate-update-and-reports-first-quarter-2026-financial-results) — Source: PTC Therapeutics, Inc.
- 2026-05-04 12:00 EST — [PTC Therapeutics to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/PTCT/ptc-therapeutics-to-participate-in-upcoming-investor-conferences) — Source: PTC Therapeutics, Inc.
- 2026-04-28 20:05 EST — [PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam](https://biopharmsignal.com/news/PTCT/ptc-therapeutics-reports-positive-topline-results-from-month-24-interim-analysis-of-pivot-hd-extension-study-of-votoplam) — Source: PTC Therapeutics, Inc.
- 2026-04-28 13:28 EST — [PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study](https://biopharmsignal.com/news/PTCT/ptc-therapeutics-to-report-results-from-pivot-hd-long-term-extension-study) — Source: PTC Therapeutics, Inc.
- 2026-04-22 12:00 EST — [PTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026](https://biopharmsignal.com/news/PTCT/ptc-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-7-2026) — Source: PTC Therapeutics, Inc.
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)